Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
KYTX 
Kyverna Therapeutics, Inc. Common Stock (KYTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: KYTX (1-star) is a SELL. SELL since 1 days. Simulated Profits (69.51%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $24
1 Year Target Price $24
| 3 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 39.7% | Avg. Invested days 28 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 300.56M USD | Price to earnings Ratio - | 1Y Target Price 24 |
Price to earnings Ratio - | 1Y Target Price 24 | ||
Volume (30-day avg) 6 | Beta - | 52 Weeks Range 1.78 - 8.45 | Updated Date 11/6/2025 |
52 Weeks Range 1.78 - 8.45 | Updated Date 11/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.68 |
Earnings Date
Report Date 2025-11-12 | When - | Estimate -1.02 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -31.08% | Return on Equity (TTM) -49.72% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 57174655 | Price to Sales(TTM) - |
Enterprise Value 57174655 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue 3341.48 | Enterprise Value to EBITDA - | Shares Outstanding 43245667 | Shares Floating 22471746 |
Shares Outstanding 43245667 | Shares Floating 22471746 | ||
Percent Insiders 12.03 | Percent Institutions 63.8 |
Upturn AI SWOT
Kyverna Therapeutics, Inc. Common Stock
Company Overview
History and Background
Kyverna Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases. Founded in 2020, it leverages advancements in cell engineering to create targeted therapies for patients with significant unmet needs.
Core Business Areas
- Cell Therapy Development: Kyverna focuses on developing engineered T cell therapies, particularly anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, to target and deplete autoreactive B cells in autoimmune diseases.
Leadership and Structure
The leadership team comprises experienced biotechnology executives and scientists. The company operates with a structure that emphasizes research and development.
Top Products and Market Share
Key Offerings
- KYV-101: KYV-101 is Kyverna's lead product candidate, an anti-CD19 CAR T-cell therapy being developed for autoimmune diseases, including lupus nephritis, systemic sclerosis, and multiple sclerosis. No specific market share data is available as it's in clinical development. Competitors include companies developing CAR-T therapies for autoimmune diseases, although few are as advanced with similar targets.
Market Dynamics
Industry Overview
The autoimmune disease market is large and growing, with significant unmet needs. Cell therapies offer a potential alternative to traditional immunosuppressants.
Positioning
Kyverna is positioned as a leader in the development of CAR T-cell therapies for autoimmune diseases, differentiating itself through its specific target and clinical focus.
Total Addressable Market (TAM)
The TAM for autoimmune disease therapies is estimated to be billions of dollars annually. Kyverna's potential share depends on the clinical success and market adoption of KYV-101.
Upturn SWOT Analysis
Strengths
- Innovative CAR T-cell therapy platform
- Experienced leadership team
- Strong focus on autoimmune diseases
- Advancing clinical programs
Weaknesses
- Early stage of development
- Reliance on a single lead product candidate
- High development costs
- Regulatory hurdles
Opportunities
- Expansion to additional autoimmune indications
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Breakthrough therapy designations
Threats
- Competition from other cell therapy developers
- Clinical trial failures
- Regulatory setbacks
- Manufacturing challenges
Competitors and Market Share
Key Competitors
- BMY
- JNJ
- ABBV
Competitive Landscape
Kyverna focuses on a specific area of the autoimmune space. Competitors have broad pipelines and approved therapies, but Kyverna aims to offer innovative cell therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by expansion and advancement of the company's pipeline, which shows significant activity.
Future Projections: Future growth depends on the clinical success of KYV-101 and other pipeline programs. Analyst estimates are not available yet.
Recent Initiatives: Advancing KYV-101 through clinical trials, expanding manufacturing capabilities.
Summary
Kyverna Therapeutics is a clinical-stage biopharmaceutical company with an innovative CAR T-cell therapy platform focused on autoimmune diseases. Its lead product, KYV-101, shows promise but is still in early development. The company's success hinges on positive clinical trial results and effective manufacturing. Competition and regulatory hurdles remain significant risks.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share estimates are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kyverna Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Emeryville, CA, United States | ||
IPO Launch date 2024-02-08 | CEO & Director Mr. Warner Biddle | ||
Sector Healthcare | Industry Biotechnology | Full time employees 129 | Website https://kyvernatx.com |
Full time employees 129 | Website https://kyvernatx.com | ||
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.